New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 9, 2013
11:24 EDTEW, MDT, BSXEdwards Lifesciences sees Sapien heart valve sales $700M-$820M, WSJ reports
Due to new competitive threats, Edwards Lifesciences says sales of its Sapien heart valves will likely be $700M-$820M next year, reports the Wall Street Journal. Analysts predicted sales of $844.7M, according to FactSet data. Chairman and CEO Michael A. Mussallem commented at the company's investor conference that the coming year will "probably be more challenging from a growth perspective than we've faced in the past." Reference Link
News For BSX;MDT;EW From The Last 14 Days
Check below for free stories on BSX;MDT;EW the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
April 14, 2014
08:59 EDTMDT, EWOn The Fly: Pre-market Movers
Subscribe for More Information
08:12 EDTEWEdwards Lifesciences price target raised to $90-$91 from $82-$83 at Wells Fargo
Wells Fargo increased its price target on Edwards after a federal court granted a preliminary injunction limiting the sale of a competing product, Medtronic's (MDT) CoreValve. The firm said the injunction was a "major surprise," and estimates that the injunction could increase Edwards EPS by 15c in 2014 and 34c in 2015. Wells keeps an Outperform rating on the stock.
07:39 EDTMDT, EWEdwards Lifesciences upgraded to Buy from Fair Value at CRT Capital
Subscribe for More Information
06:44 EDTBSXBoston Scientific upgraded at BofA/Merrill
As previously reported, BofA/Merrill upgraded Boston Scientific to Buy from Neutral. The firm upgraded shares given increased confidence in the pipeline, opportunities to increase margin, valuation, and expectations the FDA will approve the LAA product this year. Price target raised to $16.
06:22 EDTEW, MDTMedtronic downgraded to Neutral from Overweight at JPMorgan
Subscribe for More Information
06:21 EDTEW, MDTEdwards Lifesciences upgraded to Neutral from Underweight at JPMorgan
Subscribe for More Information
06:18 EDTBSXBoston Scientific upgraded to Buy from Neutral at BofA/Merrill
Price target is $16.
April 13, 2014
15:10 EDTEW, MDTMedtronic says CoreValve ruling has no impact outside U.S.
Subscribe for More Information
April 12, 2014
19:50 EDTEW, MDTEdwards says court limits sale of Medtronic CoreValve system in U.S.
Edwards Lifesciences (EW) announced that the U.S. District Court for the District of Delaware granted a preliminary injunction limiting the sale of Medtronic's (MDT) CoreValve system in the United States. The court ordered the injunction to go into effect in seven business days. The hearing related to a federal jury decision in 2010 that CoreValve willfully infringes Edwards' U.S. Andersen transcatheter aortic valve replacement patent. At the conclusion of the hearing, Chief Judge Gregory Sleet ordered Edwards and Medtronic to confer on what instances the CoreValve device could continue to be used in the treatment of U.S. patients at centers currently trained on CoreValve. There is a large body of evidence demonstrating the safety and performance of the Edwards SAPIEN valves, and the company remains committed to ensuring patients have appropriate access to transcatheter therapy. This case was initiated by Edwards in 2008. On April 1, 2010, a federal jury found Medtronic willfully infringed Edwards' U.S. Andersen patent and awarded damages. In Nov. 2012, the U.S. Court of Appeals for the Federal Circuit affirmed the jury decision; in Oct. 2013, the U.S. Supreme Court declined to hear Medtronic's appeal. The patent involved in this suit is part of the Andersen family of patents. The U.S. Andersen patent was issued in 1995. A petition has been filed with the U.S. Patent and Trademark Office to extend this patent into early 2016. In a separate case, a federal jury in January found that Medtronic CoreValve had willfully infringed Edwards' U.S. Cribier transcatheter heart valve patent, and awarded damages to Edwards in that trial.
April 10, 2014
19:10 EDTMDTMedtronic confirms FDA approval for expanded indications
Subscribe for More Information
18:34 EDTBSXBoston Scientific enrolls first patient in registry for evaluating Vercise DBS
Subscribe for More Information
16:32 EDTMDTMedtronic gets FDA approval for revised labeling application
The U.S. FDA approved an application from Medtronic for revised labeling for two cardiac resynchronization pacemakers and eight cardiac resynchronization defibrillators, expanding the indication for use to patients with atrioventricular block and less severe heart failure. The FDA previously approved these devices for patients with more severe heart failure as evaluated by their physician using specific criteria. The new approved use includes patients with less severe heart failure, but who are already indicated to receive RV pacing. With the new indication, these patients will be eligible to receive a device that will pace both sides of their heart instead of just the right. Reference Link
April 8, 2014
07:26 EDTMDT, EWElsevier Business Intelligence to hold a conference
Subscribe for More Information
April 7, 2014
18:01 EDTBSXBoston Scientific gets FDA, CE Mark clearance for Expect Slimline Needle
Boston Scientific announced it has received clearance from the U.S. FDA and CE Mark approval in Europe for the Expect Slimline Needle, which is now globally available for Endoscopic Ultrasound-Fine Needle Aspiration procedures. The Expect Slimline Needle is on contract with four leading group purchasing organizations.
07:58 EDTMDTMedtronic data positive for C.R. Bard, says Barclays
Barclays said Medtronic's (MDT) better than expected drug coated balloon data could have a positive class effect that benefits C.R. Bard (BCR). The firm reiterates its Overweight rating C.R. Bard and raised its price target to $165 from $160. Note that BofA/Merrill downgraded C.R. Bard to Neutral from Buy following the Medtronic's news.
07:38 EDTMDTMedtronic data should lead to approval of drug-coated balloon, says Wells Fargo
Subscribe for More Information
April 4, 2014
05:14 EDTEWEdwards Lifesciences INTUITY Elite valve system receives CE Mark
Edwards Lifesciences announced it has received CE Mark for the advanced EDWARDS INTUITY Elite valve system. This next-generation, rapid deployment system facilitates smaller incisions in surgical aortic valve replacement, or AVR, procedures, and is built upon extensive evidence supporting the durability of the Carpentier-Edwards PERIMOUNT heart valve design.
April 2, 2014
09:36 EDTMDTMedtronic has a conference call hosted by JPMorgan
JPMorgan Analyst Weinstein will host a conference call with CEO Omar Ishrak on April 3 at 10 am.
08:31 EDTBSX, EWSociety of American Gastrointestinal & Endoscopic Surgeons holds annual meeting
2014 Annual Meeting of SAGES is being held in Salt Lake City, Utah on April 2-5.
05:23 EDTBSXBoston Scientific reports favorable results in MADIT-CRT study
Boston Scientific reported favorable results in studies related to cardiac resynchronization therapy, or CRT, platinum chromium stent platforms and transcatheter aortic valve replacement, or TAVR. Boston Scientific announced significant findings from the continued analysis of the landmark MADIT-CRT study, demonstrating a significant and sustained survival benefit in the indicated population. The long-term results demonstrated a 41% relative reduction in the risk of death in patients who received a Boston Scientific defibrillator with CRT compared to patients who received a defibrillator alone. In addition to the mortality benefit, the results demonstrate that these patients experienced a 62% relative reduction in the risk of experiencing a first heart failure event when compared to patients who didn't receive CRT therapy. Boston Scientific released new data that continue to reinforce the advantages of platinum chromium stents. The trial compared the safety and effectiveness of the Boston Scientific Platinum Chromium Everolimus-Eluting Stent System, or PtCr EES, to the Abbott Laboratories Cobalt Chromium Everolimus-Eluting Stent System, or CoCr EES. The results show low event rates out to four years with PtCr EES confirming excellent long-term performance. At four years, the PtCr EES also continued to demonstrate advantages over the CoCr EES. The Boston Scientific Lotus Valve System advanced TAVR technology continued to demonstrate impressive performance at three months.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use